Characterizing the Immune Response and Neuronal Damage in SARS-CoV-2 Infected Individuals
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- SARS-CoV Infection
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Enrollment
- 88
- Locations
- 1
- Primary Endpoint
- Innate immune response to SARS-Cov-2
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The Investigators plan to study the innate and adaptive immune response, the inflammatory response, and associated complications such as complement activation and neurological damage in SARS-Cov-2 infected individuals. Patients with mild, moderate and severe COVID-19 disease will be enrolled.
Detailed Description
The severity of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to severe illness requiring mechanical ventilation. Immunological factors which lead to severe disease in certain COVID-19 patients remain incompletely understood. Neurological damage and complement activation may be a consequence of excess inflammation in severe COVID-19. The investigators plan to study the innate and adaptive immune response and potentially associated complications such as neurological damage and complement activation in mild, moderate and severe COVID-19 courses.
Investigators
Eligibility Criteria
Inclusion Criteria
- •PCR confirmed SARS-Cov-2 infection
Exclusion Criteria
- •Refusal to participate
- •Age \< 18 years
Outcomes
Primary Outcomes
Innate immune response to SARS-Cov-2
Time Frame: 5 days after enrollment
Measurement of HLA-DR expression on CD14+ cells (flowcytometry)
Cell mediated immune response
Time Frame: 28 days (+/-7) after enrollment
Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)
Cytokine response to SARS-Cov-2
Time Frame: 28 days (+/-7) after enrollment
Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)
Humoral immune response
Time Frame: At enrollment
Measurement of neutralizing SARS-Cov-2 antibody concentrations (plaque reduction assay)
Neurological damage
Time Frame: 28 days (+/-7) after enrollment
Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)
Secondary Outcomes
- Complement activation(28 days (+/-7) after enrollment)